FDA Post-Marketing Clinical Trial Authority Should Be Bolstered, Topol Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Cleveland Clinic researcher Topol's suggestion is part of a JAMA editorial critical of COX-2s following Pfizer's announcement that Celebrex demonstrated an increased cardiovascular risk in a cancer trial. Topol advocates for second-line use and a contraindication in high-risk patients.